ClinicalTrials.gg
CompletedNCT04162821Updated Mar 24, 2021

Study on Pharmacokinetics of Hydronidone

A Phase 1 interventional study of Hydronidone in Pharmacokinetics of Hydronidone, sponsored by Beijing Continent Pharmaceutical Co, Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-24.

Sponsored by Beijing Continent Pharmaceutical Co, Ltd. (part of GNI Group Ltd.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

To evaluate the pharmacokinetic characteristics of hydronidone capsules (specification: 30 mg/ pill) in healthy subjects And the effect of feeding on pharmacokinetics to provide evidence for phase II/III clinical trial protocols.

02

Conditions studied

  • Pharmacokinetics of Hydronidone
03

In context

Lead sponsor

Beijing Continent Pharmaceutical Co, Ltd. is the lead sponsor of 26 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy volunteers, half male and half female;
  2. Age: from 18 to 45 years old, the age difference of the same group of subjects should not be more than 10 years;
  3. Weight: male ≥50kg, female ≥45kg, 19≤≤24 (BMI= weight (kg)/height 2 (m2));
  4. Complete physical examination: vital signs, hematuria routine, blood pregnancy, blood glucose, blood lipid,Blood electrolyte, surface antigen, liver and kidney function, , and syphilis antibody test, , smoke test, urine drug screening, alcohol breath test, abdominal ultrasound examination, chest X-ray examination No abnormal or abnormal clinical significance;
  5. Detailed understanding of the nature, significance, possible benefits and possible disadvantages of the experiment has been obtained before the study I was able to communicate well with the researchers, Comply with the requirements of the entire study and be able to understand and sign written .

Exclusion criteria

Exclusion Criteria:

  1. Have participated in any other clinical trials within the first three months of the trial;
  2. Any diseases that may affect the safety of the test or the process of the drug in vivo, including But not limited to: heart, liver, kidney, endocrine, digestive tract, immune system and respiratory system Those with or existing diseases of the above system (especially those with cardiovascular diseases including cardiovascular diseases) Any gastrointestinal disease that affects drug absorption (such as irritable bowel syndrome symptoms, inflammation) History of sexual bowel), active pathological bleeding (such as peptic ulcer), urticaria, epilepsy, past Allergic rhinitis, eczema dermatitis, asthma, etc.
  3. (consultation) allergy: if there are two or more drugs, food allergies or lactose intolerance Tolerance;
  4. (consultation) any inhibition or induction of liver administration during the first 28 days of administration of the study drug Drugs for metabolism (common liver enzyme inducers: barbiturates Drugs for metabolism (common liver enzyme inducers: barbiturates such as phenobarbital, carbamazepine,Aminorumide, griseofulvin, aminopropyl, phenytoin, gluconate, rifampicin, desicer Betamethasone. Common liver enzyme inhibitors: chlorpromazine, cimetidine, ciprofloxacin, metronidazole, chlorine Mycin, isoniazid, sulfonamide, etc. Or had used any medication (pack) within 14 days prior to initial administration Including Chinese herbal medicine and health products;
  5. (consultation) have specific food requirements and cannot follow a uniform diet (such as standard meals or high fat) Food intolerance) or difficulty swallowing;
  6. (consultation) unable to tolerate venipuncture and/or having a history of blood or acupuncture;
  7. (consultation) long-term overconsumption of tea and coffee (more than 8 cups a day, 1 cup =250mL) A person who drinks coffee or caffeine; Or 48 hours before the study's first dose Foods or drinks with caffeine (such as coffee, strong tea, chocolate, etc.) affect the absorption of drugs, A special diet of distribution, metabolism, and excretion;
  8. (consultation) previous binge drinking (i.e., drinking more than 28 units per week for men and more than 28 units per week for women Drink more than 21 units of alcohol (1 unit contains 14 grams of alcohol, such as 360 mL of beer or 45 mL spirits of 40% alcohol or 150 mL wine); Or within 6 months prior to the trial Regular drinkers (more than 14 units per week); Or 24 before the first dose of the study Who has taken any alcoholic product within an hour;
  9. (consultation) study blood donation or massive bleeding (greater than 450 mL) within 3 months before initial administration. Or who plans to donate blood or blood components during or within 3 months after the study;
  10. (consultation) acute illness during the screening phase before study or before study medication;
  11. (consultation) study of patients with liver replacement containing drugs that induce or inhibit liver replacement within 24 hours before initial administration Foods or drinks containing enzymes (e.g., grapefruit, mango, pitaya, grape juice, orange juice, etc.) are abundant Rich in flavonoids or citrus glycosides);
  12. Surgery was performed within three months prior to the screening period or was planned for the duration of the study Surgery;
  13. (consultation) previous history of drug abuse; A history of drug abuse;
  14. (consultation) smoking more than 5 cigarettes per day during the 14 days before screening, or during the trial Using any tobacco products;
  15. Screening of persons who have smoked or used any tobacco products up to admission;
  16. Positive results of nicotine test;
  17. Alcohol breath test with test results greater than 0.0mg/100ml;
  18. Positive urine drug screening;
  19. Pregnant women or those who plan to become pregnant within 6 months after the end of the trial;
  20. The investigator considers that there is anything that may affect the subject's or adherence to the protocol Or participating in the test may affect the results of the test or the safety of the personnel under test.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    60mg group

    Drug: Hydronidone

  • Experimental
    90mg group

    Drug: Hydronidone

  • Experimental
    120mg group

    Drug: Hydronidone

Interventions

06

What researchers measure

Primary outcomes

  1. Plasma drug concentration

    Plasma drug concentration after administration of different doses of hydronidone

    Time frame: up to 12 weeks

07

Study locations

1 site
  • Ethics committee of drug clinical trials of huazhong university of science and technology
    Wuhan, Hubei 430030, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Nov 2019, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2019
First posted
Nov 14, 2019
StartActual
Oct 30, 2019
Primary completionActual
Nov 27, 2019
CompletionActual
Mar 1, 2021
Last update
Mar 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04162821
Responsible party
Sponsor
First posted
Nov 14, 2019
Start date
Oct 30, 2019
Primary completion
Nov 27, 2019
Completion
Mar 1, 2021
Last update
Mar 24, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydronidone

Start the discussion